A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Trial Profile

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2018

At a glance

  • Drugs Veliparib (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Rectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jan 2018 According to Trial design presented at the 2018 Gastrointestinal Cancers Symposium, the target accrual is 79 evaluable patients per arm with additional experimental arms added through protocol amendments.
    • 18 Jan 2018 According to Trial design presented at the 2018 Gastrointestinal Cancers Symposium, a second experimental arm of testing pembrolizumab concurrently with and following chemoradiotherapy is in development.
    • 18 Jan 2018 Trial design presented at the 2018 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top